Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neoantigen-loaded dendritic cell vaccine (Radboud University Medical Center)
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
01
Overview
This investigational dendritic cell (DC) vaccine, developed by Radboud University Medical Center, is an autologous cell-based immunotherapy designed for the prevention and treatment of colorectal cancer in patients with Lynch syndrome or microsatellite instability-high (MSI-H) tumors. The vaccine consists of mature dendritic cells derived from the patient and pulsed with HLA-A2-binding peptides from the tumor-associated antigen carcinoembryonic antigen (CEA) and frameshift-derived neoantigens (specifically from caspase-5 and transforming growth factor beta receptor II). These neoantigens are generated by the mismatch repair deficiency characteristic of Lynch syndrome-associated cancers. By presenting these antigens to the immune system, the vaccine aims to prime and expand tumor-specific T cells to recognize and eliminate malignant cells.
- Other names
- DC vaccinationFrameshift-derived neoantigen-loaded DC vaccineAutologous mature dendritic cells pulsed with HLA-A2-binding peptides
Beyond the preview
Go deeper on Neoantigen-loaded dendritic cell vaccine (Radboud University Medical Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neoantigen-loaded dendritic cell vaccine (Radboud University Medical Center).